By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Seattle Genetics, Inc. 

21823 - 30th Drive S.E.

Bothell  Washington  98021  U.S.A.
Phone: 425-527-4000 Fax: 425-527-4001

Committed to improving patient outcomes
At Seattle Genetics, we are committed to developing innovative antibody-based therapies that improve clinical outcomes for patients with cancer and autoimmune diseases. We are dedicated to addressing unmet medical need, and strive to achieve that goal through an unwavering commitment to excellence in clinical development.

Focusing on Clinical Development
Seattle Genetics is a clinical stage biotechnology company advancing a broad product pipeline of antibody-based therapies. Our lead program, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the FDA for patients with relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is empowered by Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. In addition, we are conducting clinical trials with four other product candidates, lintuzumab (SGN-33), dacetuzumab (SGN-40) and SGN-75, for the treatment of cancer, and SGN-70, for autoimmune diseases. We are also advancing a pipeline of promising preclinical candidates and have robust research and development capabilities that are our engine for innovation and long-term growth.

Our proprietary ADC technology empowers antibodies by stably linking them to cell-killing drug payloads. The drug payload is inactive until released from the antibody inside the targeted cancer cell, thereby sparing normal tissue the toxicity of traditional chemotherapy. In addition to brentuximab vedotin, SGN-75 is an ADC that is in a phase I clinical trial and we are developing several preclinical ADC product candidates, including ASG-5ME, which is advancing towards a planned 2010 clinical trial for solid tumors.

Expanding Our Opportunities Through Collaboration
Collaborating with leading biopharmaceutical companies is a cornerstone of Seattle Genetics' business strategy. Product-focused collaborations, such as our exclusive worldwide collaboration agreement with Genentech (a wholly owned member of the Roche Group) to develop and commercialize dacetuzumab, provide significant near- and mid-term funding while bringing in additional resources and expertise to support, advance and expand promising development programs. Collaboration and license agreements around our proprietary ADC technology also generate cash for the company - more than $75 million to date - while providing further clinical validation of the ADC platform and, in some cases, opening the door to new product development opportunities.

Key Statistics

Ownership: Public

Web Site: Seattle Genetics
Symbol: SGEN



Celera Corporation  Seeking to jointly discover and develop antibody-based therapies for cancer.

Applied Molecular Evolution/Eli Lilly 


Company News
Seattle Genetics (SGEN) Highlights Vadastuximab Talirine (SGN-CD33A) Data In Acute Myeloid Leukemia (AML) At The 21st Congress Of European Hematology Association 6/13/2016 10:56:06 AM
ASCO2016: Astellas (ALPMY) And Seattle Genetics (SGEN) Present ASG-15ME And ASG-22ME Phase I Clinical Data In Metastatic Urothelial Cancer At ASCO Annual Meeting 6/6/2016 11:24:09 AM
ASCO2016: Seattle Genetics (SGEN) And Astellas (ALPMY) Present ASG-15ME And Enfortumab Vedotin Phase I Clinical Data In Metastatic Urothelial Cancer At ASCO Annual Meeting 6/6/2016 8:31:02 AM
Seattle Genetics (SGEN) Initiates Pivotal Phase III Trial Of Vadastuximab Talirine (SGN-CD33A) For Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) 5/25/2016 10:48:20 AM
Seattle Genetics (SGEN) To Present At Upcoming Investor Conferences 5/4/2016 10:52:55 AM
Seattle Genetics (SGEN) Reports First Quarter 2016 Financial Results 4/29/2016 10:24:20 AM
Seattle Genetics (SGEN) Highlights Novel Antibody-Drug Conjugate (ADC) Technology Advances At AACR Annual Meeting 4/18/2016 11:47:02 AM
Seattle Genetics (SGEN) To Present At Upcoming Investor Conferences 3/1/2016 12:49:21 PM
Seattle Genetics (SGEN) Initiates Phase I Trial Of SGN-CD19B For Patients With B-Cell Non-Hodgkin Lymphoma 2/25/2016 10:48:26 AM
Seattle Genetics (SGEN) Initiates Phase I/II Trial Of Vadastuximab Talirine (SGN-CD33A) Combination Therapy For Patients With Untreated Myelodysplastic Syndrome (MDS) 2/22/2016 12:27:53 PM